GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (STU:N2U0) » Definitions » Profitability Rank

Adlai Nortye (STU:N2U0) Profitability Rank : 1 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Profitability Rank?

Adlai Nortye has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Adlai Nortye's Operating Margin % for the quarter that ended in Jun. 2023 was %. As of today, Adlai Nortye's Piotroski F-Score is 9999.


Competitive Comparison of Adlai Nortye's Profitability Rank

For the Biotechnology subindustry, Adlai Nortye's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Profitability Rank falls into.



Adlai Nortye Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Adlai Nortye has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Adlai Nortye's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-15.564 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Adlai Nortye has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Adlai Nortye Profitability Rank Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye (STU:N2U0) Business Description

Traded in Other Exchanges
Address
685 US Highway 1, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Adlai Nortye (STU:N2U0) Headlines

No Headlines